CA2595013C - Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee - Google Patents

Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee Download PDF

Info

Publication number
CA2595013C
CA2595013C CA2595013A CA2595013A CA2595013C CA 2595013 C CA2595013 C CA 2595013C CA 2595013 A CA2595013 A CA 2595013A CA 2595013 A CA2595013 A CA 2595013A CA 2595013 C CA2595013 C CA 2595013C
Authority
CA
Canada
Prior art keywords
fusion protein
hinge region
rhuepo
fcg
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2595013A
Other languages
English (en)
Other versions
CA2595013A1 (fr
Inventor
Haitao Wang
Yong Du
Rui Zhang
Jing Xu
Longbin Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novagen Holding Corp
Original Assignee
Novagen Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagen Holding Corp filed Critical Novagen Holding Corp
Priority to CA2595013A priority Critical patent/CA2595013C/fr
Publication of CA2595013A1 publication Critical patent/CA2595013A1/fr
Application granted granted Critical
Publication of CA2595013C publication Critical patent/CA2595013C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Une protéine de fusion ayant un polypeptide non-immunoglobuline avec un résidu cystéine proximal par rapport à lextrémité C-terminale de celui-ci, et un composant immunoglobuline avec une région darticulation ayant muté sont décrits. Dans un mode de réalisation, le composant non immunoglobine comprend des facteurs stimulant la croissance de colonies de granulocytes-macrophages humains (GM-CSF). La mutation comprend un site ayant muté par point correspondant en position à la position dans une région darticulation native du résidu cystéine situé le plus près du résidu cystéine du composant non-Ig. La distance par rapport au résidu cystéine du polypeptide non-immunoglobuline et nimporte quels résidus cystéine restants de la région darticulation ayant muté est suffisante pour empêcher la formation dune liaison disulfure entre les deux.
CA2595013A 2007-07-26 2007-07-26 Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee Active CA2595013C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2595013A CA2595013C (fr) 2007-07-26 2007-07-26 Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2595013A CA2595013C (fr) 2007-07-26 2007-07-26 Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee

Publications (2)

Publication Number Publication Date
CA2595013A1 CA2595013A1 (fr) 2009-01-26
CA2595013C true CA2595013C (fr) 2019-03-19

Family

ID=40299551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2595013A Active CA2595013C (fr) 2007-07-26 2007-07-26 Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee

Country Status (1)

Country Link
CA (1) CA2595013C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733697A1 (fr) * 2019-04-30 2020-11-04 Medizinische Hochschule Hannover Molécule de signalisation artificielle
CN113583096B (zh) * 2020-05-01 2023-06-30 清华大学 SARS-CoV-2 Spike蛋白受体结合域二聚体及其应用

Also Published As

Publication number Publication date
CA2595013A1 (fr) 2009-01-26

Similar Documents

Publication Publication Date Title
US20220127623A1 (en) Fusion proteins having mutated immunoglobulin hinge region
US20230265143A1 (en) Recombinant human epo-fc-fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
RU2530168C2 (ru) Слитные белки иммуноглобулинов
US7211253B1 (en) Erythropoietin forms with improved properties
CA2595013C (fr) Proteines de fusion renfermant un facteur gm-csf et un fragment fc ayant une region charniere modifiee
TWI554520B (zh) 在活體中具有延長之半生期以及提高之紅血球生成活性的重組人類紅血球生成素（ｅｐｏ）-ｆｃ融合蛋白
JP7136690B2 (ja) 免疫グロブリン融合タンパク質およびその使用

Legal Events

Date Code Title Description
EEER Examination request